{Reference Type}: Journal Article
{Title}: Lactoferrin as a potential therapeutic for the treatment of Candida-associated denture stomatitis.
{Author}: Krupińska AM;Bogucki Z;
{Journal}: J Oral Biosci
{Volume}: 66
{Issue}: 2
{Year}: 2024 Jun 20
暂无{DOI}: 10.1016/j.job.2024.05.007
{Abstract}: <B>BACKGROUND: </B>The use of prostheses in the oral cavity creates favorable conditions for Candida colonization, which may subsequently lead to Candida-associated denture stomatitis (CADS). Due to its many contributing factors and frequent relapses, CADS is difficult to manage. Given the rise in drug resistance among fungal species, it is critical to develop new therapeutic approaches, reduce the required dosage of medications, and minimize the toxicity and side effects of therapy.<BR><B>CONCLUSIONS: </B>Salivary lactoferrin, a multifunctional glycoprotein, is thought to be the first line of defense against microbial invasion of mucosal surfaces.<BR><B>CONCLUSIONS: </B>Current research emphasizes the capability of lactoferrin and its derivatives to eliminate a broad spectrum of Candida species. It may be an appealing option for use in monotherapy or in combination with common medications for oral stomatitis treatment. This review provides an overview of the current understanding of lactoferrin's anti-fungal effects in oral candidiasis.